期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication 被引量:2
1
作者 Synne Semb Frederik Helgstrand +1 位作者 Flemming Hjorne Peter Bytzer 《World Journal of Gastroenterology》 SCIE CAS 2017年第37期6907-6910,共4页
Magnesium deficiency can cause a variety of symptoms, including potentially life-threatening complications such as seizures, cardiac arrhythmias and secondary electrolyte disturbances. Hypomagnesemia can be a serious ... Magnesium deficiency can cause a variety of symptoms, including potentially life-threatening complications such as seizures, cardiac arrhythmias and secondary electrolyte disturbances. Hypomagnesemia can be a serious adverse effect to proton pump inhibitor(PPI) therapy, which is worrying due to the widespread use of PPIs. Current evidence suggest that the mechanism of PPI induced hypomagnesemia is impaired intestinal magnesium absorption. In this report, we present the case of a long-term PPI user with persistent hypomagnesemia with severe symptoms at presentation. He was unable to stop PPI treatment because of severe reflux symptoms, and was dependent on weekly intravenous magnesium infusions, until his magnesium levels finally normalized without the need for supplementation after a successful laparoscopic fundoplication. 展开更多
关键词 HYPOMAGNESEMIA Proton pump inhibitor Gastroesophageal reflux disease drug adverse effect Laparoscopic fundoplication
下载PDF
Current cancer therapies and their influence on glucose control 被引量:6
2
作者 Carly Yim Kerry Mansell +1 位作者 Nassrein Hussein Terra Arnason 《World Journal of Diabetes》 SCIE 2021年第7期1010-1025,共16页
This review focuses on the development of hyperglycemia arising from widely used cancer therapies spanning four drug classes.These groups of medications were selected due to their significant association with new onse... This review focuses on the development of hyperglycemia arising from widely used cancer therapies spanning four drug classes.These groups of medications were selected due to their significant association with new onset hyperglycemia,or of potentially severe clinical consequences when present.These classes include glucocorticoids that are frequently used in addition to chemotherapy treatments,and the antimetabolite class of 5-fluorouracil-related drugs.Both of these classes have been in use in cancer therapy since the 1950s.Also considered are the phosphatidyl inositol-3-kinase(PI3K)/AKT/mammalian target of rapamycin(mTOR)-inhibitors that provide cancer response advantages by disrupting cell growth,proliferation and survival signaling pathways,and have been in clinical use as early as 2007.The final class to be reviewed are the monoclonal antibodies selected to function as immune checkpoint inhibitors(ICIs).These were first used in 2011 for advanced melanoma and are rapidly becoming widely utilized in many solid tumors.For each drug class,the literature has been reviewed to answer relevant questions about these medications related specifically to the characteristics of the hyperglycemia that develops with use.The incidence of new glucose elevations in euglycemic individuals,as well as glycemic changes in those with established diabetes has been considered,as has the expected onset of hyperglycemia from their first use.This comparison emphasizes that some classes exhibit very immediate impacts on glucose levels,whereas other classes can have lengthy delays of up to 1 year.A comparison of the spectrum of severity of hyperglycemic consequences stresses that the appearance of diabetic ketoacidosis is rare for all classes except for the ICIs.There are distinct differences in the reversibility of glucose elevations after treatment is stopped,as the mTOR inhibitors and ICI classes have persistent hyperglycemia long term.These four highlighted drug categories differ in their underlying mechanisms driving hyperglycemia,with clinical presentations ranging from potent yet transient insulin resistant states[type 2 diabetes mellitus(T2DM)-like]to rare permanent insulin-deficient causes of hyperglycemia.Knowledge of the relative incidence of new onset hyperglycemia and the underlying causes are critical to appreciate how and when to best screen and treat patients taking any of these cancer drug therapies. 展开更多
关键词 Cancer therapy HYPERGLYCEMIA adverse drug effects Immune checkpoint inhibitors mTOR inhibitors 5-fluorouracil analogs GLUCOCORTICOIDS Diabetes mellitus
下载PDF
Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a
3
作者 Eckart Schott Friedemann Paul +4 位作者 Jens T Wuerfel Frauke Zipp Birgit Rudolph Bertram Wiedenmann Daniel C Baumgart 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第26期3638-3640,共3页
To alert clinicians to a potential novel adverse drug effect of interferonβ la, we herein report a patient with relapsing-remitting multiple sclerosis who developed ulcerative colitis following treatment with interfe... To alert clinicians to a potential novel adverse drug effect of interferonβ la, we herein report a patient with relapsing-remitting multiple sclerosis who developed ulcerative colitis following treatment with interferonβ la. Ulcerative colitis persisted despite discontinuation of interferonβ la treatment and switching the patient to glatiramer acetate. Tacrolimus (FK506), 6-mercaptopurine, and prednisolone were required to induce remission. Both ulcerative colitis and multiple sclerosis were eventually well controlled using this regimen. Our report underscores that caution should be exercised when prescribing immunostimulatory agents in patients with inflammatory bowel disease (IBD) and challenges current efforts to stimulate innate immunity as a novel therapeutic concept for IBD. 展开更多
关键词 Ulcerative colitis Interferonβ la TACROLIMUS Innate immunity Multiple sclerosis adverse drug effects
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部